Protean

SOL #: DARPARA2601Solicitation

Overview

Buyer

DEPT OF DEFENSE
Defense Advanced Research Projects Agency (Darpa)
DEF ADVANCED RESEARCH PROJECTS AGCY
ARLINGTON, VA, 222032114, United States

Place of Performance

Place of performance not available

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

PSC

National Defense R&D Services; Department Of Defense Military; Applied Research (AC12)

Set Aside

No set aside specified

Timeline

1
Posted
Feb 11, 2026
2
Last Updated
Mar 11, 2026
3
Submission Deadline
May 7, 2026, 4:00 PM

Qualification Details

Fit reasons
  • NAICS alignment with historical contract wins in similar service areas.
  • Scope strongly matches core technical capabilities and delivery model.
Risks
  • Past performance thresholds may require one additional teaming partner.
  • Potential clarification needed on staffing minimums before bid/no-bid.
Next steps

Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.

Quick Summary

The Defense Advanced Research Projects Agency (DARPA) has issued a Research Announcement (RA) for the "Protean" program, seeking novel research to develop medical countermeasures (MCMs) that restore protein function against chemical threat agents. This solicitation aims to protect against current and future chemical threats, focusing on targets like Acetylcholinesterase, Mu Opioid Receptor, and ion channels. The submission process involves a two-stage approach.

Purpose & Scope

DARPA's Protean program seeks to identify and develop prophylactics and/or therapeutics capable of providing complete protection against chemical threat challenges exceeding 10,000x LD50s. Key objectives include:

  • Identifying novel regulatory points for selected protein targets.
  • Characterizing chemical intoxication mechanisms for broad protection.
  • Evaluating protein conformation, binding site, or dynamic events contributing to function.
  • Developing a pipeline for optimizing chemical matter for in vivo efficacy.

Contract Details

  • Type: Research Announcement (Solicitation)
  • Award Instruments: Cooperative Agreements and Research Other Transactions Awards.
  • Period of Performance: 33 months total (Phase 1: 18 months, Phase 2: 15 months).
  • Cost Sharing: Not required, but will be considered.
  • Set-Aside: None specified.
  • Agency: Defense Advanced Research Projects Agency (DARPA).
  • Product Service Code: AC12 - National Defense R&D Services; Department Of Defense Military; Applied Research.

Submission & Evaluation

Proposals follow a two-gate submission process:

  • Gate 1 Submissions (Due March 12, 2026): Requires a Video Abstract (using the revised template) and an Abbreviated Technical Volume (using the provided template). Evaluation criteria for Gate 1 include Technical Approach, Technical Ability, Relevance to DARPA Mission, and Cost and Task Assessment.
  • Gate 2 Submissions (Due May 7, 2026): Full Proposals are by invitation only, following successful Gate 1 evaluation.
  • Eligibility: Proposers must be registered in SAM and have a Unique Entity ID. Foreign entities may participate if compliant with U.S. regulations.

Key Attachments & Requirements

Bidders must utilize provided templates for their submissions, including the Revised Video Abstract Template and the Abbreviated Technical Volume Template. Additionally, understanding and adhering to the S&T Protection Implementation Plan (PIP) Template and the Protean CUI Guide is critical, as proposers must address Controlled Unclassified Information (CUI) requirements. DARPA anticipates multiple awards.

People

Points of Contact

BAA CoordinatorPRIMARY

Files

Files

Download
Download
Download
Download
Download
Download

Versions

Version 2Viewing
Solicitation
Posted: Mar 11, 2026
Version 1
Solicitation
Posted: Feb 11, 2026
View
Protean | GovScope